Skip to content
TrialScanner

NCT03226899

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Phase 4TerminatedIRWDLeadMEDPCollaborator

Registry record

Lead sponsor
Ironwood Pharmaceuticals, Inc.
Conditions
Gout; Chronic Kidney Disease (CKD)
Primary completion
Feb 25, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03226899 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03226899: A Phase 4 Safety and... | TrialScanner